GSK plc (GSK) ORD GBP0.3125
18.00p
(0.83%)
- Add to watchlist
- Create an alert
- This stock can be held in a
18.00p
(0.83%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
18.00p
(0.83%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Director dealings: GSK chairman raises stake
6 February 2026 15:00
(Sharecast News) - GSK revealed on Friday that non-executive chairman Jonathan Symonds had acquired 2,500 ordinary shres in the FTSE 100-listed drugmaker.
-
EU gives GSK's Nucala green light for use in uncontrolled COPD
6 February 2026 07:45
(Sharecast News) - Drugmaker GSK said on Friday that the European Commission has approved Nucala (mepolizumab) as an add‑on maintenance treatment for adults with uncontrolled COPD characterised by elevated...
-
GSK sees slower sales growth in 2026 as patent loss looms
4 February 2026 07:19
(Sharecast News) - UK pharma giant GSK said turnover growth would slow this financial year as it looked to counter the expiry of an HIV drug patent and a deal with the Trump administration to lower product...
-
GSK to cut up to 350 R&D jobs across UK, US
2 February 2026 17:37
(Sharecast News) - GSK is planning to cut as many as 350 jobs in research & development in the UK and US, it was announced on Monday.
-
Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK
27 January 2026 11:36
(Sharecast News) - Analysts at Citi initiated coverage of AstraZeneca and GSK on Tuesday, taking a bullish stance on the former but a more cautious view on the latter.
-
GSK vaccine given green light for all adults in Europe
26 January 2026 07:18
(Sharecast News) - The European Commission has approved GSK's respiratory syncytial virus (RSV) vaccine for use in all adults, the drugs giant announced on Monday.
-
GSK to snap up Rapt Therapeutics in $2.2bn deal
20 January 2026 07:57
(Sharecast News) - British drugs giant GSK has agreed to buy Rapt Therapeutics in a $2.2bn deal, it was announced on Tuesday, sending shares in the American allergy specialist soaring.
-
GSK chronic hepatitis B treatment hits goal in two studies
7 January 2026 07:36
(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patients from 29 countries.
-
Japan approves GSK treatment for severe asthma
6 January 2026 07:27
(Sharecast News) - GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed "significant reductions" for patients with severe...
-
GSK's COPD treatment approved by Chinese regulators
5 January 2026 07:15
(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD).
-
GSK asthma treatment approved by US regulators
17 December 2025 07:05
(Sharecast News) - US regulators have approved GSK's Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ultra-long-acting biologic with twice-yearly dosing for this...
-
GSK secures MHRA nod for twice‑yearly respiratory treatment Exdensur
16 December 2025 07:53
(Sharecast News) - Drugmaker GSK said on Tuesday that Exdensur (depemokimab), an ultra-long-acting biologic to treat respiratory diseases, has received marketing authorisation from the UK's Medicines...
Company announcements Announcements
-
Director/PDMR Shareholding
6 February 2026 10:30
GSK
-
Nucala COPD approved by the European Commission
6 February 2026 07:00
GSK
-
Director/PDMR Shareholding
5 February 2026 15:30
GSK
-
Final Results
4 February 2026 07:00
GSK
-
Total Voting Rights
2 February 2026 15:00
GSK
-
European Commission approves Arexvy for adults 18+
26 January 2026 07:00
GSK
-
GSK to acquire RAPT Therapeutics
20 January 2026 07:05
GSK
-
Agreement on changes to ViiV minority shareholding
20 January 2026 07:00
GSK
-
Director/PDMR Shareholding
16 January 2026 15:30
GSK
-
Director/PDMR Shareholding
15 January 2026 15:30
GSK
-
Director/PDMR Shareholding
13 January 2026 15:30
GSK
-
EC approval of Shingrix PFS
7 January 2026 07:05
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2026. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.